Quantinno Capital Management LP boosted its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report) by 11.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,808 shares of the company’s stock after acquiring an additional 2,520 shares during the period. Quantinno Capital Management LP’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $527,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of FMS. Yousif Capital Management LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $209,000. Pacer Advisors Inc. lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 36.3% during the 1st quarter. Pacer Advisors Inc. now owns 198,614 shares of the company’s stock worth $4,223,000 after buying an additional 52,871 shares in the last quarter. Signaturefd LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 14.2% during the 1st quarter. Signaturefd LLC now owns 7,383 shares of the company’s stock worth $157,000 after buying an additional 918 shares in the last quarter. American National Bank purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $32,000. Finally, Legacy Wealth Asset Management LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $578,000. Hedge funds and other institutional investors own 6.66% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Truist Financial increased their price target on shares of Fresenius Medical Care AG & Co. KGaA from $26.00 to $28.00 and gave the stock a “hold” rating in a research note on Thursday, July 13th. Citigroup began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday. They issued a “neutral” rating for the company. The Goldman Sachs Group began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, July 12th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Finally, StockNews.com upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.95.
Fresenius Medical Care AG & Co. KGaA Price Performance
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last announced its earnings results on Tuesday, May 9th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.10. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $4.98 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 5.44% and a net margin of 3.06%. Equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.17 EPS for the current fiscal year.
Fresenius Medical Care AG & Co. KGaA Cuts Dividend
The company also recently announced an annual dividend, which was paid on Thursday, June 1st. Investors of record on Thursday, May 18th were given a $0.7086 dividend. The ex-dividend date of this dividend was Wednesday, May 17th. This represents a yield of 2.1%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is currently 39.62%.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
- Five stocks we like better than Fresenius Medical Care AG & Co. KGaA
- Why is the Ex-Dividend Date Significant to Investors?
- Can the Amazon Partnership Put DISH Network Back on Track?
- The How And Why of Investing in Oil Stocks
- Snap Stock: Two Steps Forward and One Step Back In?
- How to Calculate Return on Investment (ROI)
- ONSemi Is On Target For New Highs In 2023
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
